Literature DB >> 17514194

10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients.

J Nemunaitis, J S Vorhies, B Pappen, N Senzer.   

Abstract

Entities:  

Mesh:

Year:  2007        PMID: 17514194     DOI: 10.1038/sj.cgt.7701048

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


× No keyword cloud information.
  4 in total

1.  Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Authors:  Ben C Creelan; Scott Antonia; David Noyes; Terri B Hunter; George R Simon; Gerold Bepler; Charles C Williams; Tawee Tanvetyanon; Eric B Haura; Michael J Schell; Alberto Chiappori
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456

2.  Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo.

Authors:  Ju-Feng Zhang; Fang Wei; Hui-Ping Wang; Hui-Ming Li; Wei Qiu; Peng-Kang Ren; Xia-Fang Chen; Qian Huang
Journal:  J Exp Clin Cancer Res       Date:  2010-05-20

3.  New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.

Authors:  J F Spencer; J E Sagartz; W S M Wold; K Toth
Journal:  Cancer Gene Ther       Date:  2009-05-29       Impact factor: 5.987

4.  An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.

Authors:  D L Lichtenstein; J F Spencer; K Doronin; D Patra; J M Meyer; E V Shashkova; M Kuppuswamy; D Dhar; M A Thomas; A E Tollefson; L A Zumstein; W S M Wold; K Toth
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.